Magic mushroom compound tested for Post-Surgery pain and opioid addiction

NCT ID NCT07406828

Not yet recruiting Symptom relief Sponsor: Trent Emerick Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-stage trial will give a single 10 mg dose of psilocybin to 70 adults recovering from trauma surgery who also have opioid use disorder. Researchers want to see if it's safe and practical to give psilocybin in the hospital, and how it affects pain, mood, and opioid use over the next month. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin (a psychedelic drug)
What this could lead to: If it works, this could point toward a new way to help trauma surgery patients with opioid use disorder manage pain and reduce opioid dependence.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and feasibility, not effectiveness. The results may not apply to broader populations, and psilocybin can cause intense psychological effects requiring careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia opiate dependence Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAIN MANAGEMENT POSTOPERATIVE PAIN

Contacts and locations

Locations

UPMC Presbyterian

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.